-

12:41:49 PM

Latest NRXP Stock Market News

NRXP - NRX Pharmaceuticals Inc

07/27/21 11:34 AM

Nasdaq : NRXP

NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia

NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage, global biopharmaceutical company, today announced that the Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous ZYESAMI™ (aviptadil)

RHEA-AI

neutral

07/22/21 6:48 AM

Nasdaq : NRXP

covid-19

NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has validated the first commercial formulation of ZYESAMI™ (aviptadil) for intravenous use, allowing for high volume manufacture, with an anticipated one year or greater stability, under

RHEA-AI

neutral

07/19/21 6:48 AM

Nasdaq : NRXP

covid-19

NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19

NRx Pharmaceuticals (Nasdaq: NRXP), will present data at the Disease Control and Prevention Summit on July 21, 2021 at 10:10 EST, via the following link:

RHEA-AI

very negative

07/12/21 11:18 AM

Nasdaq : NRXP

partnershipcovid-19

NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine

NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage pharmaceutical company announced today that it has signed a Memorandum Of Understanding with the Government of Israel to license exclusive worldwide development, manufacturing, and

RHEA-AI

neutral

07/12/21 8:45 AM

Nasdaq : NRXP

covid-19

NRx Pharmaceuticals and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with ZYESAMIÔ (Aviptadil) in the I-SPY COVID Trial

NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP) and Quantum Leap Healthcare Collaborative ™ (Quantum Leap) have begun treating patients with inhaled ZYESAMIÔ (Aviptadil), in the I-SPY COVID Trial (NCT04488081), a phase 2 adaptive

RHEA-AI

neutral

07/06/21 9:20 AM

Nasdaq, OTC : NRXP, RLFTF

clinical trial

NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia

NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage biopharmaceutical company, today announced it is initiating clinical training of Nation of Georgia ( Georgia) ICU physicians, in the use of intravenous ZYESAMI™ (Aviptadil- acetate) for emergency

RHEA-AI

positive

06/15/21 7:33 AM

Nasdaq : NRXP

NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI™ (Aviptadil) Expanded Access Protocol

NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage pharmaceutical company, today announced positive data from its ZYESAMI™ (Aviptadil) Expanded Access Protocol (EAP). Overall, patients receiving at least one dose of ZYESAMI™ in addition to intensive care

RHEA-AI

neutral

06/01/21 6:28 AM

Nasdaq, OTC : NRXP, RLFTF

covid-19

NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure

NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage pharmaceutical company, today announced it has filed an application with U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for ZYESAMI™ (Aviptadil-acetate), to

RHEA-AI

neutral

05/27/21 6:48 AM

Nasdaq : NRXP

management

NRx Pharmaceuticals Names General H.R. McMaster to Company's Board of Directors

Today, NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced the election of The Honorable Herbert Raymond "H.R." McMaster (LTG US Army, Ret.) as a member of the company's Board of Directors, effective May 27, 2021.NRx Pharmaceuticals Names General H.R.

RHEA-AI

neutral

05/26/21 9:29 AM

Nasdaq : NRXP

covid-19

NRx Pharmaceuticals to Lead Development of COVID-19 Medicines and Vaccines in Central Europe and the Caucasus Region in Collaboration with the Lugar Institute and Cromos Pharma

Today, NRx Pharmaceuticals, Inc., (Nasdaq:NRXP) (NRx) through its Georgia subsidiary, announced that it has signed a master services agreement with Cromos Pharma, LLC, headquartered in Longview, Washington, to conduct phase 3 clinical trials of COVID-19

RHEA-AI

neutral

NRXP Data

industryMedicinal and Botanical Manufacturing
websitewww.bigrockpartners.com/spac/spac_aboutus.html
ceo
security nameNRX Pharmaceuticals Inc
issue typecs
sectorManufacturing
sic code2834
employees2
tags
address2645 N Federal Hwy Ste 230
address2
stateFlorida
cityDelray Beach
zip33483-6111
countryUS
phone13107342300

NRXP Description:

Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. Big Rock Partners' management team includes Richard Ackerman, Chairman, President, and Chief Executive Officer, and Bennett Kim, Chief Financial Officer, Chief Investment Officer, Corporate Secretary and Director.